Pharmacology of Antibiotics

1. Sisomicin: Serum Half-Life and Distribution Space in Patients with Normal and Impaired Renal Function

   • S. Roth, K. G. Naber, M. Scheer, H. Lange

   Pages 141-150

2. Serum Levels of Nalidixic Acid in Patients with Impaired Renal Function

   • G. Gundlach, G. Linzenmeier, P. Bruehl

   Pages 151-158

3. Biotransformation of the Antibiotics in the Patients and Animals with Liver Impairment

   • Otohiko Kunii, Kazufuto Fukaya, Keimei Mashimo

   Pages 159-164

4. Comparative Pharmacokinetics of Cephalosporins

   • V. P. Jakovlev, V. S. Klimova, E. A. Rudzit

   Pages 165-170

5. Ten Years’ Experience with the Blood Level Duration Test

   • Jørgen Bang

   Pages 171-176

6. Statistical Aspects of the Blood-Level Duration Test

   • Michael Weis Bentzon

   Pages 177-182

7. Effect of Recumbency on Erythromycin Absorption

   • R. L. Parsons, Gillian M. Paddock

   Pages 183-190

8. Cholestyramine Induced Antibiotic Malabsorption

   • R. L. Parsons, Gillian M. Paddock, Gillian M. Hossack

   Pages 191-198

9. Investigation of the Gastrointestinal Absorption of Ampicillin, Cephalexin and Pivampicillin

   • H. Lode

   Pages 199-203

10. Comparative Bioavailability of Oral Ampicillin Suspension, Pivampicillin Hydrochloride Salt (Capsule), Pivampicillin Pamoate Salt (Suspension) and Pivampicillin Probenecid Salt (Tablet) in Man

    • G. Hitzenberger, P. E. Wittreich, I. Jaschek, A. Korn, J. Bonelli, D. Magometschnigg

    Pages 205-211

11. Biotransformation of Ampicillin, Amoxicillin, and Oxacillin in Healthy Subjects and in Patients with Bacteriuria

    • Hedvig Graberm, T. Perenyi, Magda Arr, E. Ludwig

    Pages 213-218

12. Antibiotic Absorption in Crohn’s Disease

    • R. L. Parsons, Gillian M. Paddock, G. M. Hossack, D. M. Hailey

    Pages 219-229

13. A Pharmacokinetic Study of the Combination Rifampicin Plus Trimethoprim in Man

    • W. Brumfitt, V. M. Moss, E. Brooker, J. M. T. Hamilton-Miller

    Pages 231-236

14. The Excretion and Metabolism of Talampicillin in Rat, Dog, and Man

    • D. J. Jeffery, K. H. Jones, P. F. Langley

    Pages 237-241

15. The Excretion of Hetacillin Methoxymethyl Ester (BL-P1761) into the Prostatic Fluid of the Dog

    • Torben B. Kjaer, Paul O. Madsen

    Pages 243-247

16. Kidney Distribution of Carbenicillin, Indanyl Carbenicillin, Tobramycin, Fosfomycin and Cefazolin

    • R. Di Carlo, D. Savoia, G. Fontana, G. Ceccarelli

    Pages 249-253

17. Studies on Tissue Distribution of Antibiotics — An Attempt to Estimate Tissue Levels from Macro-Organisms

    • Jingoro Shimada, Yasushi Ueda, Motofumi Saigusa, Ryoichi Tsukuda

    Pages 255-260

18. Immune Responsiveness to β Lactam Antibiotics

    • Janet M. Dewdney, Beverley Weston

    Pages 261-271

19. Rifampicin-Induced Antibodies

    • Sheila Worlledge

    Pages 273-278

20. Possible Mechanisms in Pathogenesis of Nitrofurantoin-Induced Lung Disease

    • Peter Cole

    Pages 279-286

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

• cancer
• chemotherapy
• kinetics
• pharmacokinetics
• research
• resistance
• toxicity

• The London Hospital Medical College, London, UK

  J. D. Williams

• East Birmingham Hospital, Birmingham, UK

  A. M. Geddes

Policies and ethics